medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2020, Number 1

<< Back

Medicina & Laboratorio 2020; 24 (1)

DiGeorge/velocardiofacial syndrome: a case report

Acosta-Aragón MA, Torres-Hernández D, Fletcher-Toledo T

Language: Spanish
References: 16
Page: 69-76
PDF size: 441.16 Kb.


ABSTRACT

DiGeorge syndrome, also known as velocardiofacial syndrome or 22q11 deletion syndrome, is characterized by the congenital absence of the thymus and the parathyroid gland. The classic triad of this disorder is congenital heart disease, endocrinopathy with hypocalcemia and primary immunodeficiency. However, the syndrome may exhibit multiple pleotropic abnormalities and clinical manifestations that often result in facial dysmorphism and changes in the palate. Clinically, a high susceptibility to recurrent respiratory or gastrointestinal infections is obser- ved. In cases of thymic aplasia, treatment with prophylactic antibiotics and thymic transplantation is necessary, while in others, expectant management is used. This manuscript presents the case of an 18-month old male patient, referred to the genetics service due to several phenotypic alterations. The process by which the Di- George syndrome diagnosis, management and prognosis was reached, as well as a brief review of the literature, are presented.


REFERENCES

  1. McDonald-McGinn DM, Sullivan KE. Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Medicine (Baltimore) 2011;90:1-18.

  2. Hacihamdioglu B, Hacihamdioglu D, Delil K. 22q11 deletion syndrome: current perspective. Appl Clin Genet 2015;8:123-132.

  3. Davies EG. Immunodeficiency in DiGeorge syndrome and options for treating cases with complete athymia. Front Immunol 2013;4:322.

  4. Gao S, Li X, Amendt BA. Understanding the role of Tbx1 as a candidate gene for 22q11.2 deletion syndrome. Curr Allergy Asthma Rep 2013;13:613-621.

  5. Bassett AS, McDonald-McGinn DM, Devriendt K, Digilio MC, Goldenberg P, Habel A, et al. Practical guidelines for managing patients with 22q11.2 deletion syndrome. J Pediatr 2011;159:332-339 e331.

  6. Markert ML, Devlin BH, Chinn IK, McCarthy EA. Thymus transplantation in complete Di- George anomaly. Immunol Res 2009;44:61-70.

  7. Gennery AR. Immunological aspects of 22q11.2 deletion syndrome. Cell Mol Life Sci 2012;69:17-27.

  8. Bales AM, Zaleski CA, McPherson EW. Newborn screening programs: should 22q11 deletion syndrome be added? Genet Med 2010;12:135-144.

  9. Sullivan KE. Chromosome 22q11.2 deletion syndrome: DiGeorge syndrome/velocardiofacial syndrome. Immunol Allergy Clin North Am 2008;28:353-366.

  10. Yeoh TY, Scavonetto F, Hamlin RJ, Burkhart HM, Sprung J, Weingarten TN. Perioperative management of patients with DiGeorge syndrome undergoing cardiac surgery. J Cardiothorac Vasc Anesth 2014;28:983-989.

  11. Philip N, Reynaud R. [Hypocalcemia and microdeletion 22q11.2]. Arch Pediatr 2008;15:648- 649.

  12. Carelle-Calmels N, Saugier-Veber P, Girard- Lemaire F, Rudolf G, Doray B, Guerin E, et al. Genetic compensation in a human genomic disorder. N Engl J Med 2009;360:1211- 1216.

  13. Vásquez-Echeverri E, Sierra F, Trujillo-Vargas CM, Orrego-Arango JC, Garcés-Samudio C, Lince R, et al. Abordaje inmunológico del síndrome por deleción 22q11.2. Infectio 2016;20:45-55.

  14. Habel A, Herriot R, Kumararatne D, Allgrove J, Baker K, Baxendale H, et al. Towards a safety net for management of 22q11.2 deletion syndrome: guidelines for our times. Eur J Pediatr 2014;173:757-765.

  15. Driscoll DA, Sullivan KE. DiGeorge Syndrome: A chromosome 22q11.2 deletion syndrome. In: Ochs HD, Smith E, Puck JM, eds. Primary inmunodeficiency diseases: A molecular and genetic approach. 2a ed. Nueva York, Estados Unidos: Oxford University Press; 2007. p. 485-493.

  16. Kobrynski LJ, Sullivan KE. Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes. Lancet 2007;370:1443-1452.




2020     |     www.medigraphic.com